To further understand the underlying mechanism by which TPX2 regulates the antitumor activity of CD8+ T cells, we isolated CD8+ T cells from three fresh HCC tissues, which were divided into two groups; one group was treated with LV-NC as a control and the other was treated with LV-TPX2 for the overexpression of TPX2 (Fig. 6A). The gene discussed is CD8A; the disease is hepatocellular carcinoma.